THE USE OF A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR (RANIBIZUMAB) IN MACULAR EDEMA DUE TO EALES DISEASE
| Autor: | Seema R. Gupta, Christina J. Flaxel |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Vascular Endothelial Growth Factor Inhibitor
medicine.medical_specialty genetic structures medicine.diagnostic_test business.industry Intravitreal use General Medicine medicine.disease eye diseases Ophthalmology Optical coherence tomography Edema Eales disease Medicine In patient sense organs Ranibizumab medicine.symptom business Macular edema medicine.drug |
| Zdroj: | RETINAL Cases & Brief Reports. 6:122-124 |
| ISSN: | 1935-1089 |
| DOI: | 10.1097/icb.0b013e31821608e8 |
| Popis: | PURPOSE To report the results of intravitreal use of ranibizumab in a patient with macular edema due to Eales disease. METHOD This was an open-label, Phase 1, 6-month study of the safety and efficacy of intravitreally administered ranibizumab in patients with macular edema due to Eales disease. A single patient was eligible for the study during the 2 years of recruitment. She received 3 monthly intravitreal injections of 0.5 mg of ranibizumab for 3 months. At each of her monthly visits during the 6-month study, she was evaluated with a full ocular examination and optical coherence tomography imaging of the macula. Primary outcome measure was change in optical coherence tomography central subfield thickness at 6 months. RESULTS The central macular thickness as measured on optical coherence tomography reduced from 269 μm at baseline to 186 μm at 3 months. This reduction was transient with subsequent increase to 262 μm at the conclusion of the study at 6 months. CONCLUSION Ranibizumab use led to transient resolution of macular edema at 3 months; however, this reduction in edema was not sustained. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|